Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

about

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort

P2860

Q34264302-E5BBA9DB-5EAF-4C8B-BECB-B812DCBFD796

P2860

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

Item

http://www.wikidata.org/entity/Q44001619

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@en

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@nl

type

Item

label

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@en

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@nl

prefLabel

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@en

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@nl

P1476

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

@en

P2093

Ismail Simsek

http://www.w3.org/2001/XMLSchema#string

Yusuf Yazici

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Treatment of rheumatoid arthritis.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

When the levee doesn't break: a novel role of beta2-glycoprotein I to protect against congenital heart block.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

P304

663-666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.10.47

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22111748

http://www.w3.org/2001/XMLSchema#string

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

about

P2860

P2860

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698